# Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

> **NCT01091428** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 191 (actual)

## Conditions studied

- Ovarian Carcinoma
- Fallopian Tube Cancer
- Peritoneal Cancer
- Breast Carcinoma

## Interventions

- **DRUG:** Alisertib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01091428
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-16
- **Primary completion:** 2014-08-12
- **Final completion:** 2017-07-19
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2018-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01091428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01091428, "Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01091428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*